Impax regains rights to Parkinson's disease drug candidate

04/30/2013 | Reuters

Impax Laboratories will regain the rights to develop and market IPX066, an experimental Parkinson's disease drug, in certain countries after agreeing to end a collaboration deal with GlaxoSmithKline. The firms cited regulatory and commercialization delays in countries where GSK holds the right to sell the drug, known as Rytary in the U.S., as the reason for the deal's termination.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Systems Test - V&V Engineer - 14000008LS
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC